

imegimin concentration (ng/mL)
3000
2500
2000
1500
1000
500
0
1
2
3
4
5
6
7
8
9
10
11
12
Days
Normal renal function
Mild renal impairment
Moderate renal impairment

FIG. 1



Imegimin concentration (ng/mL)
10000
1000
100
10
1
0
4
8
12
16
20
24
Time postdose (h)
● Normal renal function
○ Mild renal impairment
■ Moderate renal impairment
– – – Lower limit of quantification (10.0 ng/mL)

FIG. 2



Imegimin concentration (ng/mL)
10000
1000
100
10
1
0
12
24
36
48
60
72
84
96
108
120
Time postdose (h)
Normal renal function
Mild renal impairment
Moderate renal impairment
Lower limit of quantification (10.0 ng/mL)

FIG. 3



imeglimin concentration (ng/mL)
3000
2500
2000
1500
1000
500
0
1
2
3
4
5
6
7
8
9
10
11
12
13
Days
Normal renal function
Severe renal impairment
- - - Lower limit of quantification (10.0 ng/mL)

FIG. 4



HbA1c (%) – LS mean change from placebo
0
-0.2
-0.4
-0.6
-0.8
-1
-1.2
7.94%
500 mg
N =75
-0.52%
**
7.85%
1000 mg
N =73
-0.94%
**
7.91%
1500 mg
N =73
-1.00%
**
** p < 0.0001

FIG. 5



HbA1c (%) – LS mean change from placebo
0
-0.2
-0.4
-0.6
-0.8
-1
-1.2
-1.4
-1.6
7.51 %
8.66 %
7.43 %
8.48 %
7.47 %
8.50 %
500 mg
1000 mg
1500 mg
N =43
N =32
N =42
N =31
N =42
N =31
-0.47%
-0.58%
-0.93%
-0.9%
-0.82%
-1.2%
*
*
**
*
**
**
p = 0.0005
p = 0.0174
p < 0.0001
p = 0.003
p < 0.0001
p < 0.0001

FIG. 6



Percentage of rescue therapy
10
5
0
PLA
500mg
1000mg
1500mg
10.70%
2.70%
2.70%
0%
N =75
N =75
N =73
N =73
**
**
**
** p < 0.05

FIG. 7A



Percentage of Responders
30
15
0
** p ≤ 0.0001
8.20%
N =75
15.70%
N =75
33.30%
N =73
32.90%
N =73
**
**
PLA
500mg
1000mg
1500mg

FIG. 7B



164.5 mg/dL
500 mg
N =75
-8.6mg/dL
164.4 mg/dL
1000 mg
N =73
-24.6mg/dL
164.8 mg/dL
1500 mg
N =73
-24.6mg/dL
**
**
** p < 0.0001
0
-5
-10
-15
-20
-25
-30
-35
FPG (mg/dL) – LS mean change from placebo

FIG. 8



AUCss24 range
simulated in
Phase 2b study
CKD 1 1000 mg BID
CKD 2 1000 mg BID
CKD 3 1000 mg BID
CKD 4 750 mg QD
0
20
40
60
80
Daily AUCss24 (ug.h/mL)

FIG. 9



Peak AUC24,ss (µg*hr/mL)
180
160
140
120
100
80
60
40
20
0
CKD3b
CKD4
Maximal AUC24,ss
500 mg BID
1500 mg QD
1000 mg BID
PXL008-008

FIG. 10



RVT-1501 500 mg BID
RVT-1501 1500 mg QD
RVT-1501 1000 mg BID
Cmax (ng/mL)
7800
6800
5800
4800
3800
2800
1800
800
CKD3b
CKD4
Total

FIG. 11



AUC(0-24) (h*ng/mL)
132000
107000
82000
57000
32000
7000
RVT-1501 500 mg BID
RVT-1501 1500 mg QD
RVT-1501 1000 mg BID
CKD3b
CKD4
Total

FIG. 12